Skip to content

Evaluate Safety and Efficacy of Innovative Medical Devices for Colostomy Patients

HydrustomaC3 - Randomized Clinical Trial to Evaluate Safety and Efficacy of Innovative Medical Devices for Colostomy Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05466721
Enrollment
45
Registered
2022-07-20
Start date
2022-06-13
Completion date
2023-12-31
Last updated
2024-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colostomy Stoma

Brief summary

The surgical ostomy process happens when it is necessary to open an organ (such as the intestine) in order to maintain a communication channel with the external environment. The need for ostomy surgery can happen as a result of illness, genetic factors, or trauma. Despite the extensive improvements in colorectal surgery, in case there is a need for total or partial extraction and exteriorization of the large intestine (colostomy), it is often necessary to perform a stoma that connects the end of the preserved intestine to the skin, in which cases it is necessary to place a a colostomy bag for stool collection. Thus, there is a substantial number of patients who need to live with a permanent abdominal stoma that significantly affects their quality of life, implying significant changes, both physical and social. It will then be necessary for patients to adjust their daily routines in order to deal with stoma care. The primary objective of this study is to evaluate the Hydrustoma C3 medical devices (plate C3, capsule C3, night bag C3) in terms of its efficacy and safety as colostomy devices. It is also a primary objective of this study to compare the health-related quality of life in patients with colostomy when using a control and Hydrustoma C3 devices.

Interventions

DEVICEHydrustoma C3

The participant will use the device for 14 days.

DEVICEColoplast Alterna

The participant will use the device for 14 days.

Sponsors

Hydrumedical
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* Written informed consent; * Male and Female patients; * Adult aged ≥ 18; * Descending and sigmoid colostomy created more than 3 months previously to the beginning of the study; * Having formed stool and using a flat ostomy appliance; * Able to understand the study procedures and fill questionaries; * Able to apply and remove the ostomy device autonomously.

Exclusion criteria

* Repeated experiences of leakage with the usual ostomy device, * Chronically liquid stools, * Peristomal skin disorders, * Known allergic reactions to components of the device, * Receiving chemotherapy, radiation therapy or steroids in the previous month

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of the device (journal of capsule/bag changes)14 daysEfficacy will be accessed by asking patients to record on a journal/diary, for each capsule/bag change, what was the reason for the change, and the occurrence and level of leakage.
Quality of life of the participant (Stoma Quality of Life questionnaire)14 daysIn order to compare stoma related quality of life in patients with colostomy when using a control device and the Hydrustoma C3 devices the Stoma Quality of Life questionnaire will be used. This questionnaire is composed of 20 questions. Example of question I worry that the bag detaches.. All questions must be answered on a scale of 1 to 4, being 1 always and 4 never.
Adverse effects14 daysSafety evaluations will be done by monitoring adverse events.
Safety of the device (Discolouration, Erosion, Tissue overgrowth score)14 daysSafety evaluations will be done by monitoring the peristomal skin using the validated Ostomy Skin tool (DET score). The DET Score is calculated by examining the peristomal skin and evaluate the skin based on the descriptions in each of the 3 domains, discolouration (D), erosion (E) and tissue overgrowth (T); and assessing the size of the area affected in each of the 3 domains. The total score is (maximum 15) calculated by adding all of the subscores from each domain together.

Secondary

MeasureTime frameDescription
Satisfaction of the participant (questionnaire)14 daysThe patients will be asked to evaluate the medical device in terms of application, discretion of the device, stoma related noise, feelings of security (confidence) and overall satisfaction of use (including comfort and impact on body image). The questionnaire has 8 questions of multiple choice (example Regarding the safety during usage of the devices, I feel: (1) very insecure; (2) moderately insecure; (3) Moderadately secure; (4) Very secure) and 1 open answer question.

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026